866-997-4948(US-Canada Toll Free)

Melanoma-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 1876 Pages

Melanoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2017, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 17, 105, 122, 10, 209, 29 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 16, 14, 1, 1, 69 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 11
Melanoma - Overview 12
Melanoma - Therapeutics Development 13
Melanoma - Therapeutics Assessment 72
Melanoma - Companies Involved in Therapeutics Development 105
Melanoma - Drug Profiles 214
Melanoma - Dormant Projects 1774
Melanoma - Discontinued Products 1801
Melanoma - Product Development Milestones 1805
Appendix 1817

List of Tables
Number of Products under Development for Melanoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Products under Development by Companies, H2 2017 (Contd..18), H2 2017
Products under Development by Companies, H2 2017 (Contd..19), H2 2017
Products under Development by Companies, H2 2017 (Contd..20), H2 2017
Products under Development by Companies, H2 2017 (Contd..21), H2 2017
Products under Development by Companies, H2 2017 (Contd..22), H2 2017
Products under Development by Companies, H2 2017 (Contd..23), H2 2017
Products under Development by Companies, H2 2017 (Contd..24), H2 2017
Products under Development by Companies, H2 2017 (Contd..25), H2 2017
Products under Development by Companies, H2 2017 (Contd..26), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..10), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..11), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..12), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

List of Figures
Number of Products under Development for Melanoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *